Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

News Daily News

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

Caitlin E. Cox

July 14, 2025

News Daily News

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

Shelley Wood

May 30, 2023

News Daily News

FDA Extends Dapagliflozin Indication Across LVEF Spectrum

Shelley Wood

May 09, 2023

News Daily News

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Michael O'Riordan

December 14, 2022

News Daily News

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Michael O'Riordan

April 29, 2022

News Daily News

FDA Approves Empagliflozin for Treatment of HFpEF

Michael O'Riordan

February 24, 2022

News Daily News

FDA Approves Dapagliflozin for CKD Patients

Michael O'Riordan

May 03, 2021

News Daily News

New FDA Indication Opens Up Use of Sacubitril/Valsartan in HFpEF

Todd Neale

February 16, 2021

News Daily News

FDA Approves Vericiguat for High-risk Patients With HF

Michael O'Riordan

January 20, 2021

News Daily News

FDA Clears Dapagliflozin for Heart Failure With Reduced Ejection Fraction

Shelley Wood

May 06, 2020

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

News Daily News

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

L.A. McKeown

October 21, 2019

News Daily News

FDA Approves Baroreflex Activation Therapy Device for Advanced Heart Failure

Todd Neale

August 19, 2019

News Daily News

Impella Heart Pumps Get Expanded Indication for Cardiogenic Shock in Setting of Cardiomyopathy

Todd Neale

February 13, 2018

Advertisement

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

FDA Extends Dapagliflozin Indication Across LVEF Spectrum

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

FDA Approves Empagliflozin for Treatment of HFpEF

FDA Approves Dapagliflozin for CKD Patients

New FDA Indication Opens Up Use of Sacubitril/Valsartan in HFpEF

FDA Approves Vericiguat for High-risk Patients With HF

FDA Clears Dapagliflozin for Heart Failure With Reduced Ejection Fraction

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

FDA Approves Baroreflex Activation Therapy Device for Advanced Heart Failure

Impella Heart Pumps Get Expanded Indication for Cardiogenic Shock in Setting of Cardiomyopathy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content